The Lancet
Journal Abbreviation: LANCET
ISSN: 0140-6736
eISSN: 1474-547X
Publisher: Elsevier
Publications (45)
CAR T-cell perspectives in lupus – Authors' reply (2024)
Schett G, Mackensen A, Mougiakakos D
Journal article
177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024)
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al.
Journal article
Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study (2024)
Chan K, Wahome E, Tsiachristas A, Antonopoulos AS, Patel P, Lyasheva M, Kingham L, et al.
Journal article
Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial (2024)
Beck J, Fung C, Strbian D, Bütikofer L, Z'Graggen WJ, Lang MF, Beyeler S, et al.
Journal article
CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis (2024)
Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spörl S, Vasova I, et al.
Journal article
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial (2024)
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schönau V, Hueber A, et al.
Journal article
Adult epilepsy (2023)
Asadi-Pooya AA, Brigo F, Lattanzi S, Blümcke I
Journal article, Review article
CD19-targeted CAR T cells in refractory antisynthetase syndrome (2023)
Müller F, Böltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, et al.
Journal article
CAR T-cell therapy in autoimmune diseases (2023)
Schett G, Mackensen A, Mougiakakos D
Journal article, Review article
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. (2023)
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, et al.
Journal article